Site, phenotype and context guide testing; exclude or treat relevant infection before immunosuppression.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Let the history guide the differential
Uveitis evaluation often needs the breadth of internal medicine: ocular inflammation may be the first or only visible sign of systemic disease. It can also remain eye-limited. A specific diagnosis is sometimes possible at the first visit; complex presentations need a stepwise synthesis of history, examination and directed investigation rather than an assumption that every case is systemic. 1
Ask about pain, redness, photophobia and visual change; record onset, duration, acute/chronic or recurrent course, laterality, severity and associated findings. Review joints, skin, oral/genital ulcers and connective-tissue symptoms, including clues to Behçet disease. Family history, social circumstances, travel and animal contact refine exposure risks without establishing infection by themselves. 1 2
Record diabetes, hypertension and other illnesses, previous ocular procedures and every topical or systemic medicine. Prior treatment can alter the examination and test sensitivity; planned corticosteroids or immunomodulators may interact with existing therapy and comorbidities. Allow enough time for a clear history and reassess unresolved questions during follow-up. 1
02Describe the anterior findings precisely
Measure acuity and intraocular pressure and examine both eyes systematically, including a dilated posterior examination when appropriate. Describe keratic precipitate (KP) size, shape and distribution. Large mutton-fat KPs and iris nodules suggest a granulomatous phenotype; fine or stellate KPs and iris atrophy may suggest viral disease or Fuchs uveitis. These clues are neither exclusive aetiological diagnoses nor proof of histological granulomas. 1 3
Grade anterior-chamber cells separately from flare: cells reflect cellular inflammation, whereas flare reflects increased aqueous protein and can persist. The export’s 1+ to 4+ range omits SUN grades 0 and 0.5+. Record the chosen grading method consistently. Hypopyon may occur with HLA-B27 disease or Behçet disease but must also prompt consideration of infection. Koeppe nodules lie at the pupil margin, Busacca nodules on the iris surface; also assess atrophy and neovascularisation. 1 4
Posterior synechiae join iris and lens and can distort or narrow the pupil; peripheral anterior synechiae involve the angle. A 360° posterior adhesion (seclusio pupillae) may cause pupil block, iris bombée and secondary glaucoma: assess urgently. Early appropriate cycloplegic/anti-inflammatory treatment may limit adhesions; established fibrotic synechiae cannot always be broken medically. Posterior synechiae are usually absent in unoperated Fuchs uveitis, a useful clue rather than an isolated diagnosis. 1 5
03Look beyond the anterior chamber
Record vitreous cells and haze, snowball cell aggregates and inferior snowbank exudates over the pars plana/ora serrata. Intermediate uveitis is defined by predominant vitreous inflammation; pars planitis is its idiopathic snowball/snowbank subset after relevant infectious or systemic causes are excluded. These terms are not interchangeable in every patient. 1 4
Describe retinal vasculitis as diffuse, segmental, periphlebitic or circumferential as observed. Look for retinitis, including haemorrhagic CMV or other herpetic disease, and multifocal or serpiginous choroiditis. Distinguish active lesions from old burned-out scars. Optic-disc swelling has several possible causes and must not automatically be labelled inflammatory. 1
Late presentation, cataract and dense vitritis may hide the fundus and increase diagnostic uncertainty and complication risk. Document the limitation, obtain suitable imaging or specialist review, and reassess the posterior segment rather than assuming it is uninvolved. Record pressure-related damage and other complications along with inflammation. 1
04Classify the dominant site before testing
SUN anatomical terminology uses the primary inflammatory site: anterior chamber for anterior uveitis (iritis/iridocyclitis), vitreous for intermediate disease, retina/choroid for posterior disease. Panuveitis involves anterior chamber, vitreous and retina/choroid without one predominant site. Describe granulomatous or nongranulomatous morphology as an additional clinical phenotype, not a replacement for site or cause. 1 4
Select tests from the phenotype and history, while retaining appropriate baseline screening such as syphilis serology. The export lists blood count/differential, ESR and CRP for many chronic, recurrent or bilateral cases and chest imaging for posterior/panuveitis; their indications depend on the clinical setting. BVA/DOG guidance also considers renal/liver tests and electrolytes according to assessment. Avoid indiscriminate panels, but do not translate targeted work-up into no screening. 1 3
05Interpret test results in their clinical context
HLA-B27 testing can help in a compatible acute or recurrent anterior phenotype, sometimes with fibrin or hypopyon, and may prompt assessment for spondyloarthritis including ankylosing spondylitis. A positive allele alone neither diagnoses systemic disease nor determines the cause of every uveitis. Sarcoidosis can affect any anatomical category; ACE and chest radiography/CT are selected clues, not independent confirmation or exclusion. Behçet disease is a clinical diagnosis using compatible recurrent oral/genital ulcers, skin and ocular findings; there is no single specific laboratory test. 1
Read a PPD/tuberculin skin test at 48–72 hours by measuring induration, not erythema. CDC risk-based positive thresholds are ≥5, ≥10 or ≥15 mm; 5–10 mm is not a universal borderline range and risk/setting determines interpretation. BCG can cause positive skin tests. IGRA (including QuantiFERON) is less affected by BCG, but systemic immunosuppression can reduce both skin-test and IGRA sensitivity. A negative result does not reliably exclude ocular TB, and a positive result does not prove active ocular infection. 1 6 7
Interpret syphilis serology using a nontreponemal test (RPR/VDRL) with a treponemal test (for example TP-PA or FTA-ABS) and the clinical history. Aqueous/vitreous PCR or intraocular antibody analysis is selected for suspected infection or unresolved atypical disease, not routine sampling of every patient. A positive compatible ocular PCR can support an organism-specific diagnosis; a negative result may not exclude it. Distinguish active infection from prior exposure and assay limitations. 1 7 8
The original twice states 85–90% HLA-B27 positivity for a described anterior phenotype. No identifiable denominator or underlying study was provided; the percentage is preserved in both tables as an unverified original claim, not a rate for all anterior uveitis or all hypopyon cases. 1
| Test | Clinical association | Details and limits |
|---|---|---|
| HLA-B27 | Compatible acute anterior uveitis, sometimes fibrin/hypopyon. | The export gives 85–90% positivity without an identifiable population or source; not a validated universal estimate. |
| TB tests | TB-compatible phenotype, often posterior or panuveitis; findings are not specific. | PPD induration at 48–72 h, risk cutoffs ≥5/≥10/≥15 mm; BCG may affect PPD, steroids may reduce sensitivity. QuantiFERON is less BCG-sensitive but not immune to false negatives. Selected ocular PCR may help; negative does not exclude TB. |
| Behçet disease | Often posterior or panuveitis, with systemic features. | Clinical criteria including recurrent oral/genital ulcers and skin findings; no single specific laboratory test. |
| Sarcoidosis | Can affect any uveitis anatomical category. | Chest radiography/CT and ACE selected in context; neither alone confirms or excludes the diagnosis. |
06Treat the cause and protect vision
Topical corticosteroids are used for many anterior presentations, often with appropriate cycloplegia. They are not adequate treatment for every posterior or intermediate inflammation. Depending on site, severity and cause, selected local or systemic therapy and monitored tapering may be needed. Steroid-sparing agents such as methotrexate are options for appropriate noninfectious chronic disease, with safety assessment and follow-up. 1
Unrecognised TB, toxoplasmosis or another infection may worsen under immunosuppression: suppression of host defence does not treat the organism. Establish the likely cause and arrange indicated antimicrobial treatment before or alongside carefully selected adjunctive anti-inflammatory therapy. Coordinate ophthalmology with rheumatology, internal medicine, dermatology or infectious diseases according to the findings; every patient does not need every specialty. Share a precise ocular description, uncertainties and a follow-up plan. 1
| Aspect | Key concept | Clinical meaning and limits |
|---|---|---|
| Approach | Think across organ systems. | A precise ocular description guides internal/rheumatological evaluation; eye-limited disease remains possible. |
| History | Foundation of the differential. | Symptoms, course, laterality, systemic review, medicines, family and social context direct testing. |
| Classification | SUN anatomy plus clinical morphology. | Use the dominant inflammatory site; granulomatous appearance does not establish cause or histology. |
| Examination | Describe diagnostic clues. | Mutton-fat versus fine/stellate KPs, Koeppe/Busacca nodules and synechiae presence/absence guide the differential. |
| HLA-B27 | Marker for a compatible anterior phenotype. | Hypopyon may occur; repeated export figure 85–90% remains unsupported without a defined study population. |
| TB testing | PPD and IGRA are immune-response tests. | Measure induration, not redness; steroids can impair PPD and IGRA, and results alone do not establish active ocular TB. |
| Behçet disease | Clinical diagnosis. | Use compatible clinical criteria, not a supposed definitive laboratory marker. |
| Synechiae | Distribution and extent matter. | Usually absent in unoperated Fuchs; early treatment may limit new adhesions. Seclusio/pupil block is urgent; fixed fibrosis may not break medically. |
| Teamwork | Consult according to findings. | Ophthalmology coordinates with internal medicine, rheumatology, dermatology or infection specialists as needed. |
| Late presentation | Complications obstruct assessment. | Cataract or dense vitritis can hide the fundus; document uncertainty, image appropriately and reassess. |
What guides the work-up?
History, dominant inflammatory site, precise examination findings and exposure risks guide selected tests and appropriate screening; no single marker determines the cause.
What requires urgent action?
Severe visual loss or pain, hypopyon, suspected infectious retinitis, pupil block or marked pressure rise needs urgent eye assessment and cause-specific treatment.
References and access status
- 1Immutable original export; attributed to Dr. Hassan Al-Dhibi
Complete original read; no recording available in export. Attribution, institutional role and purported verbatim quotations not independently verified; quotation themes are paraphrased.
- 2BVA/DOG: systematic history in uveitis (2025)
Complete one-page guidance read during review 044 on 2026-11-08 and reused here; repeat direct retrieval failed.
- 3BVA/DOG: diagnostic approach in uveitis (2022)
Complete one-page guidance read for review 044 on 2026-11-08 and reused; repeat retrieval failed. Guidance, not a diagnostic accuracy trial.
- 4SUN Working Group: standardization workshop (2005)
Nomenclature tables and text read for review 044 on 2026-11-08 and reused; repeat direct opening challenged. Consensus terminology, not treatment evidence.
- 5SUN: Classification Criteria for Fuchs Uveitis Syndrome (2021)
Abstract and indexed criteria read for review 044 on 2026-11-08; reused explicitly. Classification is not identical to clinical diagnosis.
- 6CDC: Clinical Testing Guidance for Tuberculosis—Tuberculin Skin Test
Indexed primary guidance on reading and risk-based cutoffs inspected on 2026-11-08; US criteria require local clinical context.
- 7British Thoracic Society: clinical statement for ocular tuberculosis (2022)
Indexed selected IGRA and diagnostic limitations inspected; complete statement and supplements not read.
- 8CDC: Laboratory Recommendations for Syphilis Testing, United States (2024)
Selected indexed serology recommendations inspected; complete report and treatment regimen not reviewed.
For patients
Uveitis is inflammation inside the eye. It can be limited to the eye or associated with infection or another systemic disease.
Your symptoms, eye examination and selected tests determine treatment. Tell the team about all medicines, past illnesses and relevant exposures.
Seek urgent care for new visual loss, severe pain or increasing redness; do not start or change steroid treatment without the treating team.
Marked visual loss, severe pain, hypopyon, suspected infectious retinitis or pupil block requires urgent ophthalmic assessment.